SEC Form 4 · accession 0001209191-15-069985
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce C Cozadd
Officer — Chairman and CEO · Director
Period of report
Sep 8, 2015
Accepted (ET)
Sep 9, 2015 · 7:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Sep 8, 2015 | S | 2,040 | $162.86 | D | 294,815 | D | |
| Ordinary SharesF3 | Sep 8, 2015 | S | 460 | $164.01 | D | 294,355 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The number of shares reported as being sold in this transaction represents the reporting person's pecuniary interest in the total shares sold in this transaction.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.61 to $163.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of reported shares sold at each separate price within the range set forth herein.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.99 to $164.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of reported shares sold at each separate price within the range set forth herein.